You are here

Smoking tobacco products - material contribution

Document

Malignant neoplasm of the nasopharynx - Smoking tobacco products - material contribution Factor

Last reviewed for CCPS 30 April 1997.

Investigative Documents

Claimant Report - Smoking [CRD905]

Claimant Report - Smoking [CRV905]

Preliminary questions [35153]

30303

the veteran has smoked cigarettes, cigars or pipe tobacco at some time.

22472

the veteran's malignant neoplasm of the nasopharynx is a nasopharyngeal carcinoma.

35154the veteran has established the causal connection between smoking tobacco products and VEA service for the clinical onset of malignant neoplasm of the nasopharynx.

35155the veteran has established the causal connection between smoking tobacco products and operational service for the clinical onset of malignant neoplasm of the nasopharynx.

or

35156the veteran has established the causal connection between smoking tobacco products and eligible service for the clinical onset of malignant neoplasm of the nasopharynx.

Clinical onset and operational service [35155]

35158

the veteran smoked at least 15 pack years of cigarettes or the equivalent thereof in other tobacco products before the clinical onset of the condition under consideration and, where smoking had ceased, at least some smoking was maintained in the 15 years before the clinical onset of the condition under consideration.

35160

smoking as a causal result of operational service made a material contribution to the SOP requirements for malignant neoplasm of the nasopharynx and smoking tobacco products.

Clinical onset and eligible service [35156]

35159

the veteran smoked at least 20 pack years of cigarettes or the equivalent thereof in other tobacco products before the clinical onset of the condition under consideration and, where smoking had ceased, at least some smoking was maintained in the 10 years before the clinical onset of the condition under consideration.

35161

smoking as a causal result of eligible service made a material contribution to the SOP requirements for malignant neoplasm of the nasopharynx and smoking tobacco products.